Anticancer drugs of tomorrow: apoptotic pathways as targets for drug design

Marek Los, Christof J. Burek, Christopher Stroh, Konrad Benedyk, Hubert Hug and Andrzej Mackiewicz

Apoptosis or programmed cell death is a set of ordered events that enables the selective removal of cells from tissue and is essential for homeostasis and proper function of multicellular organisms. Components of this signaling network, which include ligands, such as CD95, tumor necrosis factor (TNF) and TNF-related apoptosis-inducing ligand, as well as downstream molecules, such as caspases, Bcl-2 family members, and inhibitor-of-apoptosis proteins, which trigger and regulate apoptosis, are crucial targets for conventional drug development and gene therapy of cancer and other diseases. Here, we focus on apoptotic pathways and propose new potential molecular targets that could prove effective in controlling cell death in the clinical setting.

Developing a mechanism for the control of cell number was an essential event in the evolution of multicellular organisms. Such a control mechanism is required for organ formation during development, cellular homeostasis in adulthood, and proper function of the immune system (reviewed in [1–3]). Although, in the past, significant attention was focused on the molecular mechanisms that control cell division, recent efforts have exposed an equally elaborate cellular machinery that regulates apoptosis. Components of the apoptosis signaling cascade (including caspases), along with several other triggers and regulators, are among the most promising targets for pharmacological modulation of cell death and inflammation [4–7].

Caspase-1, -4 and -5 are crucial regulators of the secretion of inflammatory cytokines such as IL-1β, IL-18 and, indirectly, IFN-γ [8–11]. Pharmaceutical companies have therefore focused screening programs on single-caspase or caspase-subfamily-specific inhibitors (Table 1).

In addition, modulators of caspase activity are increasingly gaining interest as potential targets for drug development. In recent years, a family of caspase inhibitors called inhibitor-of-apoptosis proteins (IAPs), which bind and block active caspases, has attracted the attention of the pharmaceutical industry. This interest increased with discovery of the IAP inhibitors, second mitochondria-derived activator of caspase/direct IAP binding protein with low pi (Smac/DIABLO), and heat-inducible serine protease (A2HtrA2), which enable an additional level of apoptosis modulation [12,13]. Inhibition of IAPs might facilitate the apoptotic process if their interaction with caspases is prevented. However, when the interaction between IAPs and Smac/DIABLO becomes disrupted, caspases are inhibited, thereby resulting in anti-apoptotic activity [14].

Many tissues and organs – particularly in the immune system - use a receptor-mediated mechanism to activate apoptosis. Several cells express so-called death receptors on their surface. These directly activate caspases and induce apoptosis when stimulated by appropriate ligands (Fig. 1). A subfamily of caspases, termed apical/initiator caspases, become activated upon recruitment to the death-inducing signaling complex (DISC). This is a multi-protein complex formed on the death receptor within seconds or minutes after ligand binding [15]. Once activated, initiator caspases activate downstream effector caspases and other components of the cell-death machinery [9,16]. Modulation of the interactions between
Table 1. Novel anti-inflammatory and anticancer therapies exploring apoptotic pathways

<table>
<thead>
<tr>
<th>Targeted molecule(s)</th>
<th>Principle/compound</th>
<th>Company or Research Inst.</th>
<th>Code or Brand Name</th>
<th>Advancement</th>
</tr>
</thead>
<tbody>
<tr>
<td>TRAIL-R1 (DR-4)</td>
<td>Activatory, single-chain monoclonal antibody against TRAIL-R1</td>
<td>Cambridge Antibody Technology Group</td>
<td>TI-1, TI-2</td>
<td>Application of anti-TRAIL receptor 1 (TRAIL-R1) scFv monoclonal antibodies (TrailR-mAb) for the potential treatment of human cancers. Six lead mAbs were identified and shown to induce apoptosis in tumor cell lines expressing TRAIL-R1, with IC_{50} values in the range of 1.5–73 nM. The two most potent antibodies identified, TI-1 and TI-2, had IC_{50} values of 3.4 and 1.5 nM, respectively.</td>
</tr>
<tr>
<td>Retinoid receptor-driven transcription, synergy with TRAIL</td>
<td>Retinoid acid derivative: 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid</td>
<td>Anderson Cancer Center, Centre de Recherches Dermatologiques, Galderma</td>
<td>CD-437 AHPN</td>
<td>Mitochondria and caspase-3 dependent apoptosis. Increases expression of Bad and down-regulates Bcl-2 expression. Synergy effect between recombinant TRAIL and CD-437 observed in several cancer cell lines and in human tumor xenografts.</td>
</tr>
<tr>
<td>Caspases</td>
<td>Peptide-based, irreversible inhibitor</td>
<td>INSERM</td>
<td>IDN-5370 Pharmaceuticals</td>
<td>Protective towards apoptosis induction in cortical- and synaptic neurons. Reduces infarct size in a rodent cardiac ischemia/reperfusion model by more than 50%.</td>
</tr>
<tr>
<td>Caspases</td>
<td>Caspase inhibitor</td>
<td>Idun Pharmaceuticals</td>
<td>IDN-1965 Pharmaceuticals</td>
<td>ED_{50} by ip administration is 0.14 mg kg(^{-1}), by iv administration is 0.04 mg kg(^{-1}) and by oral administration is 1.2 mg kg(^{-1}). Protects from anti-CD95-induced death and liver damage in murine system [91]. Increased survival in a Gaq-40 transgenic mouse model of heart failure (left ventricular hypertrophy, left ventricular dysfunction). All treated animals showed improved fractional shortening and reduced left ventricular end-diastolic diameter compared with control, placebo-treated animals.</td>
</tr>
<tr>
<td>Caspases</td>
<td>Caspase inhibitor, preference towards caspase-8</td>
<td>Maxim Pharmaceuticals</td>
<td></td>
<td>Animal study demonstrate protection of liver cells from TNF- or galactosamine-induced apoptosis in a murine model [92].</td>
</tr>
<tr>
<td>Caspases</td>
<td>Caspase inhibitor</td>
<td>Vertex Pharmaceuticals</td>
<td>VX-799 Pharmaceuticals</td>
<td>A potent small molecule caspase inhibitor, VX-799 was very effective in several animal models of bacterial sepsis. Clinical trials in preparation.</td>
</tr>
<tr>
<td>Caspases</td>
<td>Caspase inhibitor</td>
<td>Merck Frosst</td>
<td>M-920 (L-826,920)</td>
<td>Strongly reduces mortality (~80%) in a murine and rat sepsis model by preventing from sepsis-related apoptosis of B- and T-cells [45].</td>
</tr>
<tr>
<td>Caspase-3</td>
<td>Highly selective caspase-3 inhibitor</td>
<td>Merck Frosst</td>
<td>MF-286 and MF-867</td>
<td>Highly-selective caspase-3 dipeptide-inhibitor, based on valyl-homoglycine-benzylmercaptoacetylketone, IC_{50} value: 6 nM, 38-fold selectivity over caspase-7 and more than a 1000-fold selectivity over other caspases. IC_{50} value in whole cells: of 0.5 to 1.6 µM.</td>
</tr>
<tr>
<td>Targeted molecule(s)</td>
<td>Principle/compound</td>
<td>Company or Research Inst.</td>
<td>Code or Brand Name</td>
<td>Advancement</td>
</tr>
<tr>
<td>---------------------</td>
<td>--------------------</td>
<td>---------------------------</td>
<td>--------------------</td>
<td>-------------</td>
</tr>
<tr>
<td>Caspase-3</td>
<td>Highly selective caspase-3 inhibitor</td>
<td>Merck Frosst</td>
<td>M-791 (L-826,791)</td>
<td>Strongly reduces mortality (~80%) in a murine and rat sepsis model by preventing from sepsis-related apoptosis of B- and T-cells [45]</td>
</tr>
<tr>
<td>Caspase-1, −4</td>
<td>Selective inhibitor originated from specific substrate peptide motif</td>
<td>Vertex Pharmaceuticals, Aventis Pharma AG</td>
<td>Pralnacasan VX–740, HMR–3480</td>
<td>In a Type II collagen-induced rat rheumatoid arthritis model, pralnacasan is effective at 50 mg/kg bid, for over 60 days; well tolerated in animal models [93] Encouraging results in Phase I clinical studies, currently in Phase II trials for rheumatoid arthritis treatment</td>
</tr>
<tr>
<td>Caspase-3</td>
<td>Recombinant caspase-3 linked to an antibody</td>
<td>Immunex</td>
<td></td>
<td>Recombinant caspase-3 linked to the antibody Herceptin (Genentech) tested in animal tumor model</td>
</tr>
<tr>
<td>Caspases</td>
<td>Caspase activator</td>
<td>Maxim Pharmaceuticals</td>
<td>MX-2060</td>
<td>‘Small molecule’ caspase activator, a potential anticancer agent Tested in human cancer xenograft animal models</td>
</tr>
<tr>
<td>Caspase-3</td>
<td>Selective activation of caspase-3</td>
<td>Merck Frosst</td>
<td></td>
<td>Caspase-3 zymogen is maintained in an inactive conformation by a regulatory triple Asp-motif, so called “safety-catch”, localized within a flexible loop near the large-subunit/small-subunit junction [34] The inhibitory mechanism depends on electrostatic interaction Screen for ‘small molecules’ capable of disrupting the interaction is in progress</td>
</tr>
<tr>
<td>Bcl-2</td>
<td>Antisense 18-mer-oligonucleotide, (Phosphorothioate)</td>
<td>Genta</td>
<td>G-3139, Genasense</td>
<td>Promising results in combination with a standard chemotherapy [94] Phase I/II studies of Genasense have demonstrated an excellent safety profile with toxicity observed in 20% of patients, fatigue in 10% and rash in 5%, the symptoms reverse upon withdrawal of treatment In Phase III trials for malignant melanoma [59]</td>
</tr>
<tr>
<td>Survivin</td>
<td>Antisense oligodeoxy-nucleotides</td>
<td>Isis Pharmaceuticals/ Abbott Laboratories</td>
<td></td>
<td>Following transfection of antisense oligonucleotides to mouse survivin mRNA, a time- and dose-dependent increase in polyploidy of approx. 2- to 3-fold and induction of apoptosis were observed in most of the tumor cell lines [89]</td>
</tr>
<tr>
<td>Smac/DIABLO</td>
<td>Exclusive rights patented</td>
<td>Idun Pharmaceuticals</td>
<td></td>
<td>Exclusive rights to develop Smac-based therapy have been patented Screening program focusing on Smac modulators have been started</td>
</tr>
<tr>
<td>26S Proteasome</td>
<td>Proteasome inhibition Dipeptide boronic acid</td>
<td>Millennium Pharmaceuticals</td>
<td>PS-341</td>
<td>Transient inhibition of the proteasome induces selective apoptosis in cancer cells [95] PS-341 was well tolerated and had significant single and combination antitumor activity for several cancers Phase II clinical trials against multiple myeloma and in malignancies with multiple drug resistance Significant antiangiogenic activity</td>
</tr>
</tbody>
</table>
DISC components, or triggering of death receptors by naturally occurring or artificial ligands, might enable cell death to be controlled for therapeutic purposes. This review discusses various components of the apoptotic machinery as potential targets for the development of therapeutic strategies.

Receptor-triggered apoptosis: perspectives and limits

Previous approaches to cancer therapy in mice, using either tumor necrosis factor (TNF) or CD95L – both members of the death-ligand family – have failed owing to severe systemic toxicity and hepatotoxicity, respectively. Recently, another death-ligand family member, TNF-related apoptosis-inducing ligand (TRAIL) has been cloned and characterized [17]. Several promising studies have reported that TRAIL potently induces apoptosis in transformed or virally infected cells, but has little or no detectable cytotoxic effects in normal and non-transformed cells. Moreover, no overall toxicity was observed during in vivo studies in mice and monkeys [18,19]. Preclinical safety studies in primates (cynomolgus monkeys) showed no adverse reactions even after the administration of substantial doses of recombinant TRAIL (10 mg kg⁻¹ day⁻¹) [19]. The severe liver toxicity (massive hemorrhagic liver necrosis) that halted the in vivo testing of CD95L and TNF was not observed with the TRAIL treatment.

An important feature of TRAIL treatment is an apparent strong synergistic effect when combined with anticancer drugs or irradiation. The potentiation of cytotoxicity is most apparent in tumor cells that do not respond to treatment with either agent alone. The specific details of the underlying mechanism(s) of the potentiating effect are not known. However, they might include: (1) transcriptional induction of death receptor-4- (DR4) and DR5-TRAIL receptors (DR4–TRAIL-R1 and DR5-TRAIL-R2); (2) reduced expression of apoptosis-inhibitory molecules such as Bcl-2.
Bcl-XL or c-FLICE-inhibitory protein (c-FLIP); and (3) upregulation of pro-apoptotic proteins such as caspase-8, FADD, Smac and HtrA2. Malignancies such as acute leukemia, breast cancer, colon cancer, lung cancer and melanoma, among other malignant proliferative disorders that do not respond to standard treatment, regained sensitivity when supplemented with TRAIL [20–25].

An interesting, novel mechanism-of-action underlies the synergistic effect of all-trans retinoid acid (and its derivatives), combined with TRAIL (Table 1). 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (also known as CD-437) not only synergizes with TRAIL, but also induces its expression, thus killing target cells in a TRAIL-autocrine or -paracrine manner [26]. The synergistic effects of TRAIL and retinoids have been shown in several malignancies including acute leukemia, lung cancer and prostate cancer [24,27,28]. However, concerns were raised following a study reporting that some primary cells, particularly hepatocytes, were sensitive to TRAIL [29]. However, this appears to depend on both the way the recombinant protein was engineered and the way the primary cells were prepared. Although the data from clinical studies using TRAIL are not available yet, the in vitro and animal experiments show the significant therapeutic potential of this molecule.

Caspases: modulators of apoptosis and cytokine maturation

Mammalian caspases form a large family comprising at least 12 members. They can be divided into subfamilies having distinct roles in cell (patho)physiology based on their differential substrate specificity, structural differences of their zymogens, preferred cellular localization, and known roles in cellular processes. As they can proteolytically cleave selected cellular proteins, apoptosis is irreversible [16,30–32]. Some caspases, including caspase-1, -4 and -5, function primarily as cytokine activators. Maturation-by-proteolysis of some key pro-inflammatory cytokines, including IL-1β and IL-18, enables their immediate secretion without the time-consuming de novo synthesis. The cell thereby saves valuable time by immediately mobilizing appropriate immunological responses upon pathogen invasion. Moreover, upon viral attack, proteolytic signaling allows to mount a proper reaction
under circumstances when shutting-off the cellular transcription and translation machinery is a powerful defense mechanism by itself. In addition to their well-established role in cell death and cytokine maturation, there is some evidence that caspases might be involved in other crucial cellular processes, including activation, differentiation, and cell-cycle progression [33]. Although these areas of caspase action still remain to be defined, they could be responsible for the unexpected effects observed in the pharmacological targeting of caspases.

Modulators of caspase activity are currently the focus of both commercial and academic research (Table 1). Discovering selective inhibitors of inflammatory-caspases (caspase-1, -4 and -5) might help to control various auto-immuno-aggressive diseases, such as rheumatoid arthritis, as well as acute life-threatening conditions such as sepsis. Inhibition of apoptotic caspases might help to slow-down or even stop the progression of degenerative diseases such as Alzheimer's or spinal lateral sclerosis. By contrast, selective activation of caspases, or at least lowering the activation threshold, might help to combat cancer and eradicate some chronic viral infections. As indicated in Table 1, caspases are by far the most popular targets for the development of drugs that potentially modulate the apoptotic process. Caspase-3, the key effector caspase in apoptosis, is inhibited by an intramolecular electrostatic interaction, facilitated by a stretch of three aspartic acid molecules, termed the ‘safety-catch’ [34]. This discovery raises hope for the rapid development of small pharmacologically active molecules capable of lowering the threshold of activation, or even activating the caspase on its own.

Significant advancements have been made in the search for specific caspase inhibitors. Proof-of-principle experimental data in animal models indicate that caspase inhibition improves various conditions, including myocardial infarct (Table 1) or stroke-related ischemia/reperfusion injury of the brain, liver and other organs [35–37]. This protective effect is at least in part related to the limitation of the inflammatory response by caspase inhibition [38,39]. Efforts to design inhibitors that control the subfamily of inflammatory caspases were undertaken long before the role of caspases in apoptosis was known. Gene-disruption experiments in mice confirmed the role of mouse caspase-1 and -11 (the latter is the mouse homolog of human caspase-4 and -5) in the propagation of the acute inflammatory response that relies on IL-1β and other cytokines [40,41]. Caspase-1(-/-) mice have a major defect in the production of mature IL-1β and impaired IL-1α synthesis. Secretion of TNF and IL-6 in response to lipopolysaccharide (LPS) stimulation was also diminished in targeted animals. In addition, macrophages from caspase-1(-/-) mice are defective in LPS-induced IFN-γ production [42] owing to their inability to secrete mature IL-18. The mice are also highly resistant to lethal doses of endotoxin [43]. A corresponding phenotype was observed by caspase-11(-/-) mice [44]. The pro-inflammatory role of caspase-1 was strengthened by the finding that pharmacological blockage or genetic deletion of caspase-1 decreased necrosis, edema formation, and serum levels of amylase and lipase (both enzymes are indicators of pancreatic damage) during experimentally induced pancreatitis [44].

Caspase inhibitors were also highly protective in a sepsis model (cecal ligation and puncture) in both mouse and rat [45]. Treatment with either the broad-spectrum caspase inhibitor M-920 or the caspase-3-specific M-791 (both developed by the Merck Frosst Center; http://www.merckfrosst.ca) resulted in an equally protective response for the two molecules. Both inhibitors protected 80–90% of animals, whereas only 10–20% of control animals (treated with either solvent or the inactive molecule) survived the experiment. The protective effect can probably be attributed to the prevention of sepsis-related death of T- and B-cells undergoing apoptosis during sepsis [46,47].

Mitochondrial death pathway: pro- and anti-apoptotic Bcl-2 family members as drug targets

Bcl-2 was the first apoptosis inhibitor to be discovered, and its potential oncogenic function was evident from frequent amplified expression in lymphomas [48,49]. Since then, more family members have been cloned and characterized [50–53]. The family comprises both anti-apoptotic proteins (e.g. Bcl-2 and Bcl-XL) and pro-apoptotic proteins (e.g. Bax and Bid) (Fig. 1). In healthy cells, both subfamilies remain in equilibrium. Anti-apoptotic Bcl-2 family members inhibit cell death by blocking cytochrome c release from mitochondria [54,55], thereby preventing activation of the apoptosome pathway. By contrast, Bax and a truncated form of Bid induce both cytochrome c release and caspase activation in vitro [56] and in vivo [57]. Overexpression of Bcl-2 could provide a survival advantage for cancer cells and has been associated with increased frequency of lymphoma development in a mouse model [49]. Loss of the pro-apoptotic protein Bax function might play a role in the pathogenesis of colorectal cancers [58].

Mitochondrial cytochrome c release frequently occurs following the induction of apoptosis by chemotherapy, radiation and most other death stimuli. Together with (d)ATP, pro-caspase-9, and Apaf-1, cytochrome c contributes to apoptosome formation and subsequent activation of caspases (Fig. 1). Bcl-2 prevents cytochrome c release, thereby blocking cell death, and is therefore a suitable target for the development of anticancer therapies. Bcl-2 is
frequently overexpressed in various malignancies, most commonly in a group of B-cell non-Hodgkin’s lymphomas that have a t(14;18) chromosomal translocation.

**Targeting Bcl-2 by antisense strategy**

Modulation of Bcl-2 expression is in the most advanced stage of drug development compared with all other apoptosis-based approaches. Genta (http://www.genta.com/) has designed several antisense sequences targeting different parts of the gene encoding Bcl-2, thus inhibiting its expression to varying degrees. Genasense (Table 1), the most promising antisense phosphorothioate, is highly specific for Bcl-2 mRNA. In preclinical studies using human xenografts in a severe combined immunodeficiency (SCID) mouse lymphoma model, Genasense was more effective than Cytoxan (Bristol-Myers Squibb; http://www.bristol-myers.com), the drug used in the treatment of lymphoma. A combination of Genasense with Cytoxan significantly potentiated the efficacy of treatment. Similar results were obtained in other studies where Genasense was combined with Taxetir (Bristol-Myers Squibb; http://www.bristol-myers.com) – currently the most effective drug for the treatment of breast cancer – in nude mice bearing xenografts of human breast cancer. Taxetir and Genasense were equally effective in prolonging the lifespan of the mice; moreover, a combination of the two drugs led to full remission of the tumor in all treated mice. These animals remained tumor free for at least 180 days, compared with control animals, which died at around day 10.

In a model of human melanoma xenografted into nude mice, Genasense in combination with dacarbazine (DTIC; Boehringer-Ingelheim; http://www.boehringer-ingelheim.de) halted tumor growth, whereas DTIC alone had a weaker effect. Genasense treatment has demonstrated a biological response in Phase-I and -II clinical trials. The most promising data were obtained from patients with lymphoma, where a sustained and complete reversal of the disease was demonstrated. One patient with an advanced stage of lymphoma showed complete remission following 18 months of treatment. In addition, Genasense effectively decreased Bcl-2 protein expression in melanoma tumors and, combined with chemotherapy, induced partial remission of late-stage melanomas. In a study of 25 patients with advanced-stage melanoma, and with a life expectancy of <6 months, all patients responded to a combination of standard therapy and treatment with Genasense; life expectancy increased to ~17 months. Patients with acute myeloid leukemia also responded well to Genasense; Bcl-2 was virtually eliminated after 5–7 days of treatment. Subsequent treatment with conventional chemotherapy resulted in complete remission.

In one bladder-cancer patient who was particularly resistant to chemotherapy, a single treatment of Genasense resulted in a reduction of tumor size. Phase-I and -II studies of Genasense have shown good safety profiles, with minor toxicity restricted to <20% of patients [59,60].

**D-RNAi**

Another promising gene-regulatory approach is mRNA-antisense DNA interference (D-RNAi) – a novel post-transcriptional mechanism that silences gene expression by transfection of mRNA-antisense-DNA hybrids. Highly potent and sustained inhibition of Bcl-2 expression was observed in human prostate cancer LNCaP cells, the human CD4(+) T-cell line H9, as well as in chicken embryos [61]. Moreover, the D-RNAi-based strategy inhibited HIV-1 replication in an experimental system using HIV-1 viral gene expression. D-RNAi was found to have long-term gene-knockout effects resulting from a post-transcriptional gene silencing mechanism that might involve the homologous recombination of intracellular mRNA and the mRNA components of a D-RNAi construct [62]. Thus, D-RNAi is another potential strategy that enables the development of novel therapeutics against cancer and viral infections.

**Limitations of Bcl-2 family-based therapies**

The application of antisense-based therapies is limited to tumors outside the CNS. Oligonucleotides are unable to cross the blood–brain barrier and therefore cannot be used to treat brain metastases and brain tumors. In addition, clinical studies only partially support the negative prognostic value of Bcl-2 overexpression in hematological malignancies or solid tumors [63]; the probable reason is the influence of Bcl-2 family members on cell proliferation. Bcl-2 is phosphorylated at the G2–M transition and delays the re-entry of resting NIH-3T3 cells into the cell cycle [64]. Moreover, Bcl-2 transgenic mice have impaired T-cell proliferation, whereas transgenic overexpression of Bax accelerates cell-cycle progression and apoptosis [64,65]. Cells overexpressing Bcl-2 also have decreased levels of phosphorylated retinoblastoma protein – the key regulator of the G1 checkpoint [66]. In addition, down-regulation of Bcl-2 by antisense approaches enhances proliferation of acute myeloid leukemia cells [67]. Moreover, mutations that suppress the anti-apoptotic activity of Bcl-2 also prevent inhibitory effects on cell-cycle transition, indicating that these two activities of Bcl-2 involve partially overlapping pathways [33,64,68]. Large-scale phase III clinical trials of Genasense and related antisense-based approaches will certainly pinpoint the clinical relevance of the Bcl-2 family members in oncogenesis.
Targeting the Bcl-2 family by small molecules

The bioavailability problems of antisense- or D-RNAi-based therapeutics could be overcome by small molecules that either target crucial protein–protein interactions or mimic certain protein domains. BH3-domains of Bcl-2 family proteins are perfect candidates for this approach owing to their small size (~10 amino acids). Several in silico lead molecules have been discovered based on crystallography data [69,70]. However, subsequent verification experiments using wet-screen or cellular assays only partially supported the potential of this approach for fast and reliable drug discovery [71,72].

IAPs, Smac/DIABLO and Omi/HtrA2: modulation of the advancing apoptotic process

Activation of caspases in a cell is not equal to the induction of apoptosis. Regulatory and effector functions of caspases during erythropoiesis and cytokine maturation indicate the presence of active caspases in cells under physiological conditions [3,33,73]. The quantity and cellular localization of caspases, and the abundance of their specific inhibitors probably determines the fate of the cell.

A significant amount of attention has been given to IAPs, a family of molecules that contain baculoviral repeat (BIR) domains and, in some cases, a zinc RING-finger domain [74]. The family members – X-linked IAP (XIAP), Livin/ML-IAP, cIAP-1 and cIAP-2 – are thought to inhibit apoptosis through direct interaction with caspases, although some of these proteins are also involved in additional signaling pathways [75,76]. The most potent of these caspase inhibitors, XIAP, selectively inhibits one of the active forms of caspase-9 (p35–p12 heterotrimer) through an interaction involving its BIR3 domain and the small subunit (p12) of caspase-9. By contrast, the BIR2 domain of XIAP, along with a few crucial adjacent residues, is required to inhibit active caspase-3 and –7 [14,77,78]. Thus, XIAP interferes with death receptor- and apoptosis-mediated apoptosis by inhibiting both initiator and effector caspases.

The activity of IAPs is regulated by Smac/DIABLO, which is a structural homolog of the Drosophila proteins, Reaper, Hid and Grim [79,80]. In a similar way to cytochrome c, this protein is released into the cytosol during the early stages of apoptosis and activates caspases by inhibiting IAPs, particularly XIAP. Smac does not resemble any mammalian protein with known function and represents a novel apoptosis regulator. Upon overexpression, it sensitizes cells towards death stimuli [12]. Research programs aimed at identifying molecules that mimic Smac are in only early stages (Table 1). Nevertheless, owing to the relatively low molecular mass of Smac (24 kD), and its relatively small interaction surface with IAPs, screening programs for pharmacologically active small molecules could soon fulfill expectations [81].

The development of an IAP-based anticancer strategy could be more challenging than for Smac. Inhibitor-of-apoptosis proteins are the broadest caspase inhibitors in the cell, but also the most heterogeneous. So far, eight human IAP family members are known, most of which contain more than one BIR-domain. Collectively, they contain a total of 16 inhibitory BIR-domains. Therefore, it would be almost impossible to target all of the domains with a single small-molecule inhibitor. However, the differential, tissue-specific expression pattern of IAPs offer the possibility of selective, tissue-specific modulation of caspase activity. For example, IAP-inhibiting molecules that do not target neuronal apoptosis inhibitory protein (NAIP or neuronal IAP) would be less toxic to the CNS. Alternatively, careful engineering of antisense molecules that target conserved sequences of BIRs could lead to the development of global inhibitors of IAP expression.

Another mitochondrial protein, Omi/HtrA2, which can bind and inhibit XIAP has recently been identified [82,83]. Omi is a mitochondria-localized serine protease. During apoptosis, Omi is released from mitochondria and inhibits the function of XIAP in a similar way to Smac. Binding of Smac and Omi can antagonize the binding of XIAP to caspase-9 and thereby modulate the caspase cleavage activity of the apoptosome. The magnitude of the apoptotic stimulus, as well as the cellular levels of Smac, Omi, XIAP and other as-yet unidentified proteins, might contribute to the sensitivity of a particular cell type to apoptosis. Thus, Omi is also a promising target for the pharmacological modulation of apoptosis.

Significant attention has also been given to survivin (Table 1), another IAP-family member that has been found to inhibit cell death by binding to caspases and the pro-apoptotic Smac [79,84]. Survivin is specifically expressed in the late G2-phase and the M-phase of the cell cycle and appears to function as both a cell-cycle regulator and an apoptosis suppressor [85]. At the start of mitosis, survivin associates with microtubules of the mitotic spindle apparatus. Interestingly, caspase-3 and the cyclin-dependent kinase inhibitor p21Waf1 also co-localize with survivin at the centrosomes. Interfering with survivin function induces caspase-3 activity and apoptosis, producing a defect characterized by hyperploidy, multinucleation, and super-numerary centrosomes [85]. The role of survivin in the inhibition of apoptosis was recently challenged by a group who claim that it primarily functions in mitosis [86]. Indeed, survivin-like proteins that play a role exclusively...
in karyokinesis have been identified in yeasts and \textit{C. elegans}. Several of these genes show similar intron–exon structure, particularly around the BIR-encoding sequences \cite{87,88}. Nevertheless, regardless of whether survivin functions as a caspase inhibitor in addition to controlling karyokinesis-related events, its downregulation would certainly affect the growth of a transformed cell. Initial experiments targeting survivin with specific ribozymes or with antisense nucleotides, induced apoptosis in various cell-lines, or eliminated cisplatin resistance \cite{89}. Based on these promising results, Isis Pharmaceuticals (http://www.isip.com) and Abbott Laboratories (http://abbott.com) (Table 1) have launched the development of antisense-based strategies that target the expression of survivin \cite{89}.

**Concluding remarks**

The future of cancer therapy will be characterized by personalized treatment and the careful selection of therapeutic targets. Rapidly developing screening techniques, such as DNA microarrays, together with proteomics, will certainly help to achieve this goal. Advancements in oncogene-directed treatments using mechanisms of uncontrolled proliferation will require a better understanding of the numerous aberrations that contribute to the development of malignant diseases. The combination of agents that target different functions of a given oncoprotein complex or different physiological processes, such as differentiation and apoptosis (e.g. CD-437, TRAIL and chemotherapeutics), are expected to be more effective than single-agent protocols. Trials of multi-agent protocols without the need to test them individually should help to bring effective therapies into the clinic at a faster rate. In addition to the antisense and D-RNAi experiments mentioned here, the evaluation of small, interfering RNAs for gene silencing \cite{90} could be important for diseases where aberrant gene-regulation plays a major role. A better understanding of the basis of cancer biology should yield drugs that target molecular or genetic aberrations in tumors. Such an endeavor will continue to expand in the coming decades and will be facilitated by knowledge from the Human Genome Project.

**Acknowledgements**

This work was supported by research grants: LO823/1-1 Deutsche Forschungsgemeinschaft (DFG), IZKF-E8, LO210110 Innovative Medizinische Forschung (IMF) and 01-1893-Lo I (Deutsche Krebshilfe), issued to M.L. We apologize to those authors whose work was not cited or discussed owing to space limitations.

**References**


Li, P. et al. (1995) Mice deficient in IL-1 β-converting enzyme are defective in production of mature IL-1 β and resistant to endotoxic shock. *Cell* 80, 401–411.


78 Sun, C. et al. (2000) NMR structure and mutagenesis of the third Bir domain of the inhibitor of apoptosis protein XIAP. *J. Biol. Chem.* 275, 33777–33781
84 Tamm, I. et al. (1998) IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. *Cancer Res.* 58, 5315–5320

**Drug Discovery Today online**

High quality printouts (from PDF files)
Links to other articles, other journals and cited software and databases

All you have to do is:

Obtain your subscription key from the address label of your print subscription

Go to [http://www.drugdiscoverytoday.com](http://www.drugdiscoverytoday.com)

Click on the ‘Claim online access’ button

Click on the ‘Personal Subscription Access’ button

When you see the BioMedNet login screen, enter your BioMedNet username and password.

If you are not already a member please click on the ‘Register’ button to join.

You will then be asked to enter your subscription key.

Once confirmed you can view the full-text of *Drug Discovery Today*

If you get an error message please contact Customer Services (info@elsevier.com). If your institute is interested in subscribing to print and online please ask them to contact ct.subs@qss-uk.com

www.drugdiscoverytoday.com 77